-
1
-
-
35148880584
-
Numeric, verbal, and visual formats of conveying health risks: Suggested best practices and future recommendations
-
Lipkus IM,. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making. 2007; 27: 696-713.
-
(2007)
Med Decis Making.
, vol.27
, pp. 696-713
-
-
Lipkus, I.M.1
-
2
-
-
0023324565
-
Perception of risk
-
Slovic P,. Perception of risk. Science. 1987; 236: 280-285.
-
(1987)
Science.
, vol.236
, pp. 280-285
-
-
Slovic, P.1
-
3
-
-
38849143239
-
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
-
Siegel CA, Levy LC, Mackenzie TA, et al. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1-6.
-
(2008)
Inflamm Bowel Dis.
, vol.14
, pp. 1-6
-
-
Siegel, C.A.1
Levy, L.C.2
MacKenzie, T.A.3
-
4
-
-
0347991877
-
The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients
-
Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31.
-
(2004)
Gastroenterology.
, vol.126
, pp. 19-31
-
-
Colombel, J.F.1
Loftus, Jr.E.V.2
Tremaine, W.J.3
-
5
-
-
34548490280
-
Crohn's disease patients' risk-benefit preferences: Serious adverse event risks versus treatment efficacy
-
Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007; 133: 769-779.
-
(2007)
Gastroenterology.
, vol.133
, pp. 769-779
-
-
Johnson, F.R.1
Ozdemir, S.2
Mansfield, C.3
-
6
-
-
58149191718
-
Are adult patients more tolerant of treatment risks than parents of juvenile patients?
-
Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009; 29: 121-136.
-
(2009)
Risk Anal.
, vol.29
, pp. 121-136
-
-
Johnson, F.R.1
Ozdemir, S.2
Mansfield, C.3
-
7
-
-
0028908691
-
Communicating the benefits of chronic preventive therapy: Does the format of efficacy data determine patients' acceptance of treatment?
-
Hux JE, Naylor CD,. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making. 1995; 15: 152-157.
-
(1995)
Med Decis Making.
, vol.15
, pp. 152-157
-
-
Hux, J.E.1
Naylor, C.D.2
-
8
-
-
35148872098
-
A meta-analysis of the effects of presenting treatment benefits in different formats
-
Covey J,. A meta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Making. 2007; 27: 638-654.
-
(2007)
Med Decis Making.
, vol.27
, pp. 638-654
-
-
Covey, J.1
-
9
-
-
67949112671
-
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis
-
Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7: 874-881.
-
(2009)
Clin Gastroenterol Hepatol.
, vol.7
, pp. 874-881
-
-
Siegel, C.A.1
Marden, S.M.2
Persing, S.M.3
-
10
-
-
0030666187
-
The role of numeracy in understanding the benefit of screening mammography
-
Schwartz LM, Woloshin S, Black WC, et al. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med. 1997; 127: 966-972.
-
(1997)
Ann Intern Med.
, vol.127
, pp. 966-972
-
-
Schwartz, L.M.1
Woloshin, S.2
Black, W.C.3
-
11
-
-
0036370180
-
Numeracy and the medical student's ability to interpret data
-
Sheridan SL, Pignone M,. Numeracy and the medical student's ability to interpret data. Eff Clin Pract. 2002; 5: 35-40.
-
(2002)
Eff Clin Pract.
, vol.5
, pp. 35-40
-
-
Sheridan, S.L.1
Pignone, M.2
-
12
-
-
33847319314
-
The effectiveness of a primer to help people understand risk: Two randomized trials in distinct populations
-
Woloshin S, Schwartz LM, Welch HG,. The effectiveness of a primer to help people understand risk: two randomized trials in distinct populations. Ann Intern Med. 2007; 146: 256-265.
-
(2007)
Ann Intern Med.
, vol.146
, pp. 256-265
-
-
Woloshin, S.1
Schwartz, L.M.2
Welch, H.G.3
-
13
-
-
12244292659
-
Patients' understanding of risk associated with medication use: Impact of European Commission guidelines and other risk scales
-
Berry DC, Raynor DK, Knapp P, et al. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf. 2003; 26: 1-11.
-
(2003)
Drug Saf.
, vol.26
, pp. 1-11
-
-
Berry, D.C.1
Raynor, D.K.2
Knapp, P.3
-
14
-
-
34548572844
-
Making numbers matter: Present and future research in risk communication
-
Fagerlin A, Ubel PA, Smith DM, et al. Making numbers matter: present and future research in risk communication. Am J Health Behav. 2007; 31 (Suppl 1): S47-S56.
-
(2007)
Am J Health Behav.
, vol.31
, Issue.SUPPL. 1
-
-
Fagerlin, A.1
Ubel, P.A.2
Smith, D.M.3
-
15
-
-
34248549602
-
Numeracy skill and the communication, comprehension, and use of risk-benefit information
-
Peters E, Hibbard J, Slovic P, et al. Numeracy skill and the communication, comprehension, and use of risk-benefit information. Health Aff (Millwood). 2007; 26: 741-748.
-
(2007)
Health Aff (Millwood).
, vol.26
, pp. 741-748
-
-
Peters, E.1
Hibbard, J.2
Slovic, P.3
-
16
-
-
85047697559
-
Frequency or probability? A qualitative study of risk communication formats used in health care
-
Schapira MM, Nattinger AB, McHorney CA,. Frequency or probability? A qualitative study of risk communication formats used in health care. Med Decis Making. 2001; 21: 459-467.
-
(2001)
Med Decis Making.
, vol.21
, pp. 459-467
-
-
Schapira, M.M.1
Nattinger, A.B.2
McHorney, C.A.3
-
17
-
-
44949242296
-
Immunosuppressant medications and mortality in inflammatory bowel disease
-
Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 1428-1435; quiz 1436.
-
(2008)
Am J Gastroenterol.
, vol.103
, pp. 1428-1435
-
-
Lewis, J.D.1
Gelfand, J.M.2
Troxel, A.B.3
-
18
-
-
33646147141
-
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
-
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621-630.
-
(2006)
Clin Gastroenterol Hepatol.
, vol.4
, pp. 621-630
-
-
Lichtenstein, G.R.1
Feagan, B.G.2
Cohen, R.D.3
-
19
-
-
48949107161
-
-
National Safety Council. Available at:. Accessed July 22.
-
Odds of Dying, National Safety Council. Available at:. Accessed July 22, 2006.
-
(2006)
Odds of Dying
-
-
-
20
-
-
0027131566
-
Intestinal cancer risk and mortality in patients with Crohn's disease
-
Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology. 1993; 105: 1716-1723.
-
(1993)
Gastroenterology.
, vol.105
, pp. 1716-1723
-
-
Munkholm, P.1
Langholz, E.2
Davidsen, M.3
-
21
-
-
70350684087
-
One year data from the SONIC study: A randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy
-
Sandborn W, Rutgeerts P, Reinisch W, et al. One year data from the SONIC study: A randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology. 2009; 136: A-116.
-
(2009)
Gastroenterology.
, vol.136
, pp. 116
-
-
Sandborn, W.1
Rutgeerts, P.2
Reinisch, W.3
-
22
-
-
65349165683
-
Using a drug facts box to Communicate drug benefits and harms: Two randomized trials
-
Schwartz LM, Woloshin S, Welch HG,. Using a drug facts box to Communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009; 150: 516-527.
-
(2009)
Ann Intern Med.
, vol.150
, pp. 516-527
-
-
Schwartz, L.M.1
Woloshin, S.2
Welch, H.G.3
-
23
-
-
0034132356
-
How to do without steroids in inflammatory bowel disease
-
discussion 58.
-
Present DH,. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis. 2000; 6: 48-57; discussion 58.
-
(2000)
Inflamm Bowel Dis.
, vol.6
, pp. 48-57
-
-
Present, D.H.1
-
24
-
-
0027997229
-
A comparison of budesonide with prednisolone for active Crohn's disease
-
DOI 10.1056/NEJM199409293311304
-
Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994; 331: 842-845. (Pubitemid 24289711)
-
(1994)
New England Journal of Medicine
, vol.331
, Issue.13
, pp. 842-845
-
-
Rutgeerts, P.1
Lofberg, R.2
Malchow, H.3
Lamers, C.4
Olaison, G.5
Jewell, D.6
Danielsson, A.7
Goebell, H.8
Thomsen, O.O.9
Lorenz-Meyer, H.10
Hodgson, H.11
Persson, T.12
Seidegaord, C.13
-
25
-
-
0034798807
-
Review article: The limitations of corticosteroid therapy in Crohn's disease
-
Rutgeerts PJ,. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther. 2001; 15: 1515-1525.
-
(2001)
Aliment Pharmacol Ther.
, vol.15
, pp. 1515-1525
-
-
Rutgeerts, P.J.1
-
26
-
-
0037018761
-
Maintenance infliximab for Crohn's disease: The ACCENT i randomised trial
-
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
-
(2002)
Lancet.
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtenstein, G.R.3
-
27
-
-
33745923468
-
A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3,500 patients with Crohn's disease, multiple sclerosis (MS), and rheumatoid arhtiritis (RA) previously treated with natalizumab in clinical trials
-
Sandborn WJ, Targan SR,. A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3,500 patients with Crohn's disease, multiple sclerosis (MS), and rheumatoid arhtiritis (RA) previously treated with natalizumab in clinical trials. Gastroenterology. 2006; 130: A-72.
-
(2006)
Gastroenterology.
, vol.130
, pp. 72
-
-
Sandborn, W.J.1
Targan, S.R.2
-
28
-
-
21744455700
-
Review article: Practical management of inflammatory bowel disease patients taking immunomodulators
-
Siegel CA, Sands BE,. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005; 22: 1-16.
-
(2005)
Aliment Pharmacol Ther.
, vol.22
, pp. 1-16
-
-
Siegel, C.A.1
Sands, B.E.2
-
29
-
-
0024457688
-
6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
-
Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989; 111: 641-649.
-
(1989)
Ann Intern Med.
, vol.111
, pp. 641-649
-
-
Present, D.H.1
Meltzer, S.J.2
Krumholz, M.P.3
-
31
-
-
0038109994
-
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: A prospective cohort study
-
Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003; 125: 32-39.
-
(2003)
Gastroenterology.
, vol.125
, pp. 32-39
-
-
Vermeire, S.1
Noman, M.2
Van Assche, G.3
|